These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29136177)

  • 1. Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions.
    Ohara S; Kanda S; Okuma H; Goto Y; Horinouchi H; Fujiwara Y; Nokihara H; Ito Y; Yamamoto N; Usui K; Homma S; Ohe Y
    Jpn J Clin Oncol; 2018 Jan; 48(1):82-88. PubMed ID: 29136177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.
    Shiono A; Imai H; Endo S; Katayama K; Sato H; Hashimoto K; Miura Y; Okazaki S; Abe T; Mouri A; Kaira K; Masubuchi K; Kobayashi K; Minato K; Kato S; Kagamu H
    Radiol Oncol; 2024 Sep; 58(3):432-443. PubMed ID: 39287161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Versus Concurrent Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for N3 Limited-Stage Small-Cell Lung Cancer.
    Wang Z; Wan J; Liu C; Li L; Dong X; Geng H
    Cancer Control; 2020; 27(1):1073274820956619. PubMed ID: 32951452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of time of radio-chemotherapy and other therapeutic factors on treatment results in patients with limited disease small cell lung cancer.
    Sas-Korczynska B; Sokolowski A; Korzeniowski S
    Lung Cancer; 2013 Jan; 79(1):14-9. PubMed ID: 23153659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older.
    Shukuya T; Takahashi T; Harada H; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi K; Yamamoto N
    Jpn J Clin Oncol; 2013 Feb; 43(2):176-83. PubMed ID: 23225910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study.
    Akagi K; Taniguchi H; Fukuda M; Yamazaki T; Ono S; Tomono H; Suyama T; Shimada M; Gyotoku H; Takemoto S; Yamaguchi H; Dotsu Y; Senju H; Soda H; Mizowaki T; Monzen Y; Ikeda T; Nagashima S; Tasaki Y; Nakamura D; Komiya K; Nakatomi K; Sasaki E; Hirakawa K; Mukae H
    Thorac Cancer; 2022 Aug; 13(16):2404-2409. PubMed ID: 35808894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoradiotherapy duration correlates with overall survival in limited disease SCLC patients with poor initial performance status who successfully completed multimodality treatment.
    Manapov F; Klöcking S; Niyazi M; Belka C; Hildebrandt G; Fietkau R; Klautke G
    Strahlenther Onkol; 2012 Jan; 188(1):29-34. PubMed ID: 22189436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.
    Winther-Larsen A; Hoffmann L; Moeller DS; Khalil AA; Knap MM
    Acta Oncol; 2015; 54(9):1574-81. PubMed ID: 26203924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma.
    Sun Y; Duan Q; Chen X; Chen W; Jin X; Wu R
    Clin Transl Oncol; 2017 Dec; 19(12):1498-1506. PubMed ID: 28589432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
    Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL
    Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
    Salama JK; Pang H; Bogart JA; Blackstock AW; Urbanic JJ; Hogson L; Crawford J; Vokes EE
    Lung Cancer; 2013 Dec; 82(3):436-40. PubMed ID: 24396884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
    Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer.
    Colaco RJ; Huh S; Nichols RC; Morris CG; D'Agostino H; Flampouri S; Li Z; Pham DC; Bajwa AA; Hoppe BS
    Acta Oncol; 2013 Apr; 52(3):506-13. PubMed ID: 23438357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis.
    Niho S; Kubota K; Yoh K; Goto K; Ohmatsu H; Nihei K; Ohe Y; Nishiwaki Y
    J Thorac Oncol; 2011 Apr; 6(4):796-800. PubMed ID: 21258253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of patient gender in limited-disease small-cell lung cancer treated with chemoradiotherapy.
    Roengvoraphoj O; Eze C; Niyazi M; Li M; Hildebrandt G; Fietkau R; Belka C; Manapov F
    Strahlenther Onkol; 2017 Feb; 193(2):150-155. PubMed ID: 27853828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
    Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
    Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.
    Vrankar M; Stanic K; Jelercic S; Ciric E; Vodusek AL; But-Hadzic J
    Radiol Oncol; 2021 Nov; 55(4):482-490. PubMed ID: 34821136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.